Wafik El-Deiry: Raghavendra Vadla about GBM cell state plasticity mediated by BRD2 and therapeutic resistance

Wafik El-Deiry shared a post about Raghavendra Vadla speaking at the AACR Grantee Summit. Read his post on X below:

“Dr. Raghavendra Vadla at UC San Diego Health speaks about GBM cell state plasticity mediated by BRD2 and therapeutic resistance.

Mesenchymal subtype is the most invasive and most therapy resistant.

He spoke about RelA acetylation and with mutation of RelA there was less BRD2 and BRD4 binding to chromatin. KD of BRD2 decreased mesenchymal genes.”

More posts featuring Wafik El-Deiry.

Wafik S. El-Deiry, MD, PhD, FACP, FRSM, is the Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University and Director of the Joint Program in Cancer Biology at Brown University and affiliated hospitals.

He is the Editor in Chief at Oncotarget. Dr. El-Deiry discovered p21(WAF1) as a p53 target gene, cell cycle inhibitor, and tumor suppressor that explained the mammalian cell stress response. Dr. El-Deiry’s research is focused on mechanisms of therapy resistance with major efforts in drug discovery and development.